Quest Diagnostics Incorporated (NYSE:DGX) reported Q2 2026 revenue of $3.04B (+10.2%), net income $320M and adj. EPS $3.12 (+19.1%), lifted guidance to $11.95–12.05B revenue and $11.05–11.25 adj. EPS, while UBS kept NYSE:DGX at Neutral, calling the stock fairly valued.Previous Week RecapThis is an…
Explore more price target data and ratings for Quest Diagnostics Incorporated on the Forecasts tab, and track all previous and future analyst recommendations for Quest Diagnostics Incorporated in the dedicated News Flow.Select reference data provided by FactSet. Copyright © 2026 FactSet Research Sy…
Explore more price target data and ratings for Quest Diagnostics Incorporated on the Forecasts tab, and track all previous and future analyst recommendations for Quest Diagnostics Incorporated in the dedicated News Flow.Select reference data provided by FactSet. Copyright © 2026 FactSet Research Sy…
Quest Diagnostics reported results for the quarter ended 2026 with revenue of $3.04B, net income of $320M and diluted EPS of $2.84, each up versus the prior-year quarter.Financial Highlights¹ Reported as “Net revenues”. ² Reported as “Net income attributable to Quest Diagnostics”. ³ Reported as “Di…
Q2 2026 saw 10.2% revenue growth to $3.04B, driven by strong DIS volume from new partnerships, while net income rose 13.4% to $320M and diluted EPS increased 15% to $2.84. Operating margin declined slightly as higher costs were offset by productivity gains and ongoing cost-saving initiatives.Origin…
Q2 2026 saw over 10% revenue growth and a 19% rise in adjusted EPS, driven by strong demand across all channels and operational improvements. Full-year guidance was raised, with robust performance in advanced diagnostics and stable financial metrics.Based on Quest Diagnostics Incorporated [DGX] Q2…
